Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367971 | 0.89 | KMT2A (0.38) | KMT2AIRAK4TSHRALDH1A1PDE3B | |
| SCHEMBL31367978 | 0.87 | PDE3B (0.38) | KMT2AIRAK4TSHRALDH1A1PDE3B | |
| SCHEMBL31367976 | 0.84 | KMT2A (0.41) | KMT2AIRAK4TSHRALDH1A1MEN1 | |
| SCHEMBL31367970 | 0.78 | IRAK4 (0.35) | KMT2AIRAK4TSHRALDH1A1PDE3B | |
| SCHEMBL31367981 | 0.77 | ADORA1 (0.36) | KMT2ATSHRMEN1HSD17B10TNKS | |
| SCHEMBL31367998 | 0.76 | POLB (0.39) | KMT2ATSHRALDH1A1MEN1TNKS | |
| SCHEMBL31367991 | 0.74 | ADORA3 (0.36) | KMT2AMEN1TNKSTNKS2HPGD | |
| SCHEMBL29294068 | 0.73 | NLRP3 (0.47) | KMT2AIRAK4TSHRALDH1A1MEN1 | |
| SCHEMBL29294075 | 0.73 | NLRP3 (0.49) | KMT2AIRAK4TSHRALDH1A1PDE3B | |
| SCHEMBL31367967 | 0.72 | NLRP3 (0.45) | KMT2AIRAK4TSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092051-A1 | NLRP3 MODULATORS AND USE THEREOF | Bioentropy Inc. (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092051-A1 | NLRP3 MODULATORS AND USE THEREOF | NLRP3, NLRP1, NOD1 | KMT2A 1509/4885IRAK4 51/4885TSHR 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.